Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis shows early allo-HSCT improves overall survival in higher-risk MDS, suggesting UCBT as a viable alternative.

Early allo-HSCT significantly improved overall survival at 3 years, achieving 70% compared to 50% for later transplants.
Transplant-related mortality was lower in the early HSCT group at 22.7% versus 46.5%, indicating better outcomes for timely interventions.
The study involved 70 higher-risk MDS patients stratified by diagnosis-to-transplant interval and pre-transplant treatments affecting outcomes.
UCBT offered a lower rate of chronic graft-versus-host disease, supporting its use when sibling donors are not available.

Geng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows early allo-HSCT improves overall survival in higher-risk MDS, suggesting UCBT as a viable alternative.

Early allo-HSCT significantly improved overall survival at 3 years, achieving 70% compared to 50% for later transplants.
Transplant-related mortality was lower in the early HSCT group at 22.7% versus 46.5%, indicating better outcomes for timely interventions.
The study involved 70 higher-risk MDS patients stratified by diagnosis-to-transplant interval and pre-transplant treatments affecting outcomes.
UCBT offered a lower rate of chronic graft-versus-host disease, supporting its use when sibling donors are not available.

Geng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark